SG Capital Dumps Nearly 732,000 Haemonetics Shares Worth $59.1 Million

SG Capital Management LLC significantly reduced its stake in Haemonetics Corporation (HAE) during Q3, selling 731,892 shares for an estimated $45.3 million and decreasing its allocation within the fund's AUM from 4.7% to 0.8%. This substantial divestment occurs despite a recent 35% surge in HAE's stock price following slightly improved full-year revenue guidance, which still projects modest growth after a Q2 revenue decline, and against a backdrop of significant underperformance relative to the S&P 500 over the past year.

Analysis

SG Capital Management LLC significantly divested from Haemonetics Corporation (HAE) in Q3, reducing its stake by 731,892 shares, an estimated $45.3 million transaction based on average quarterly pricing. This substantial reduction decreased HAE's allocation within the fund's 13F AUM from 4.7% to a mere 0.8%, signaling a strong bearish sentiment from a major institutional investor. The remaining stake is valued at $8.5 million as of September 30, suggesting a potential move towards a full exit.

Haemonetics' shares have underperformed significantly, declining 14.1% over the past year and trailing the S&P 500 by 27.5 percentage points as of November 6, 2025. Despite this, the stock recently surged 35% in two days following Q2 earnings, driven by slightly improved full-year adjusted revenue guidance, now projected between a 1% decline and a 2% increase. However, Q2 revenue still declined 5% year-over-year, or 1.8% excluding currency and divestitures.

The substantial institutional selling by SG Capital, which appears to be moving towards an exit, contrasts sharply with the recent positive market reaction to HAE's guidance. This divergence suggests a cautious outlook from some institutional players despite short-term positive price action. The company's TTM revenue stands at $1.33 billion with $168.19 million in net income, but its long-term growth trajectory remains a concern given recent revenue declines.

Key Decisions for Investors

• Consider the significant institutional divestment by SG Capital as a potential long-term bearish indicator, despite recent short-term price appreciation.
• Monitor Haemonetics' future revenue reports closely, as recent top-line declines and modest full-year guidance suggest ongoing growth challenges.
• Evaluate the sustainability of the recent 35% stock surge, considering the company's historical underperformance against the S&P 500 and the mixed fundamental signals.